exclus
viral
wheez
evw
asthma
phenotyp
occur
predominantli
young
children
common
upper
respiratori
tract
viral
infect
without
progress
chronic
airway
inflamm
persist
symptom
associ
atop
asthma
aftermath
evw
detect
adult
life
confirm
exist
experiment
young
adult
due
difficulti
perform
invas
measur
young
children
littl
inform
cellular
mechan
evw
age
group
opportunist
bronchoalveolar
lavag
bal
anaesthesia
shown
rel
absenc
inflammatori
cell
children
viral
wheez
episod
contrast
atop
asthma
publish
data
inflamm
respiratori
tract
episod
viral
wheez
although
evid
suggest
respiratori
tract
inflamm
like
involv
come
studi
inflamm
upper
respiratori
tract
urt
lower
respiratori
tract
lrt
healthi
asthmat
volunt
experiment
infect
usual
human
rhinoviru
hrv
urt
inflamm
cold
well
describ
predominantli
involv
neutrophil
influx
releas
cytokin
chemokin
attract
activ
inflammatori
cell
airway
mucosa
sampl
nasal
secret
solubl
mediat
includ
groa
eosinophil
cation
protein
ecp
lrt
tract
also
known
becom
inflam
viral
exacerb
classic
atop
asthma
two
studi
suggest
recruit
neutrophil
eosinophil
studi
acut
sever
asthma
attack
thought
due
cold
high
number
neutrophil
togeth
high
concentr
found
spontan
expector
sputum
second
studi
six
classic
asthmat
cold
found
modest
sputum
neutrophilia
togeth
high
level
ecp
compar
convalesc
valu
sputum
eosinophil
differenti
count
elev
latter
despit
evid
activ
releas
ecp
inher
difficulti
exist
studi
infect
includ
time
onset
infect
potenti
differ
problem
collect
invas
sampl
young
children
episod
viral
wheez
establish
model
evw
employ
experiment
infect
use
human
coronaviru
hcov
young
adult
histori
wheez
viral
urt
infect
urti
hcov
second
preval
common
cold
viru
known
associ
exacerb
asthma
children
wheez
also
symptom
may
import
studi
virus
hrv
previous
report
lrt
symptom
increas
bronchial
respons
evw
subject
occur
symptomat
infect
effect
independ
atopi
report
analysi
model
test
hypothes
symptomat
experiment
urti
hcov
qualit
quantit
differ
lower
respiratori
tract
cellular
infiltr
distinguish
subject
evw
control
cellular
chang
seen
lrt
qualit
similar
natur
seen
urt
associ
quantit
chang
lrt
symptom
chang
bronchial
respons
studi
design
symptom
score
physiolog
measur
report
elsewher
describ
briefli
subject
paid
four
visit
clinic
trial
unit
leicest
children
asthma
centr
well
clinic
physiolog
observ
nasal
lavag
sputum
induct
carri
day
immedi
preced
viru
inocul
repeat
day
later
time
morn
h
princip
aim
studi
mechan
underli
urti
lrt
respons
categor
subject
primarili
symptomat
respons
laboratori
confirm
viral
infect
act
adjunct
valid
model
assist
categor
subject
borderlin
symptom
adult
smoke
least
year
recruit
studi
nineteen
healthi
volunt
recruit
local
advertis
histori
evw
recruit
three
local
univers
health
centr
gave
histori
two
episod
wheez
urti
last
year
wheez
nocturn
earli
morn
wheez
cough
allergen
dust
pollen
anim
wheez
wheez
respons
cold
air
interv
cold
mean
durat
rang
histori
year
one
subject
previous
label
asthmat
none
use
inhal
corticosteroid
use
agonist
relief
urti
none
admit
hospit
respiratori
ill
previou
year
subject
suffer
urti
month
preced
particip
studi
atop
statu
assess
skin
prick
test
reaction
dermatophagoid
pteronyssinu
cat
fur
mix
grass
pollen
compar
control
soluprick
alk
frederiksberg
denmark
subject
classifi
atop
basi
one
posit
skin
prick
test
defin
weal
greater
mm
diamet
neg
control
studi
approv
leicestershir
health
author
research
ethic
committe
written
inform
consent
obtain
particip
viral
wheezer
atop
control
seven
atop
inocul
nasal
tissu
cultur
infect
dose
hcov
previous
describ
subject
monitor
develop
symptom
diari
spirometri
methacholin
bronchial
challeng
perform
prior
sampl
collect
visit
previous
describ
techniqu
nasal
lavag
involv
subject
sit
neck
extend
warm
salin
ad
inulin
mgml
introduc
one
nostril
occlud
inulin
use
marker
dilut
measur
inulin
concentr
wash
solut
nasal
lavag
fluid
nlf
obtain
proport
nlf
consist
nasal
secret
calcul
process
subject
occlud
soft
palat
posit
oral
pressur
wash
remain
nasal
caviti
expel
steril
receptacl
kept
ice
weigh
process
within
h
total
ml
aliquot
ml
insert
altern
nostril
ml
total
per
nostril
sputum
induc
use
standard
method
briefli
subject
inhal
salbutamol
metr
dose
inhal
volumat
spacer
min
inhal
nebul
salin
three
period
min
ultrason
nebul
medix
ltd
harlow
uk
output
mlmin
mass
median
diamet
mouthpiec
sputum
expector
subject
blown
nose
gargl
minim
nasal
oral
contamin
sputum
store
ice
weigh
process
within
h
cell
process
perform
assess
qualiti
sampl
cell
viabil
sputum
squamou
contamin
count
leucocyt
perform
differenti
cell
count
process
follow
commonli
use
previous
valid
method
sputum
includ
plug
select
dispers
four
time
volum
dithiothreitol
dtt
sigma
pool
uk
give
final
concentr
gentl
rock
min
dilut
four
volum
dulbecco
salin
filtrat
nylon
gauz
nlf
process
similar
way
addit
dilut
minim
use
dtt
concentr
skip
second
dilut
step
sampl
centrifug
g
min
supernat
remov
aliquot
store
total
cell
count
obtain
use
neubauer
haemocytomet
fisher
scientif
loughborough
uk
cell
viabil
assess
trypan
blue
exclus
method
cell
suspens
adjust
cellsml
cell
suspens
use
prepar
cytospin
rpm
min
use
shandon
iii
cytocentrifug
shandon
southern
instrument
sewickley
pa
usa
cytospin
stain
diff
quick
stain
dade
behr
switzerland
code
third
parti
least
cell
count
low
power
order
categor
squamou
cell
bronchial
nasal
ciliat
epitheli
cell
leucocyt
express
percentag
possibl
least
leucocyt
count
high
power
order
determin
sputum
nlf
leucocyt
differenti
nlf
leukocyt
differenti
multipli
total
cell
count
adjust
dilut
effect
nasal
wash
gave
concentr
cell
per
millilitr
nasal
secret
supernat
store
measur
enzym
immunoassay
opteia
kit
pharmingen
san
diego
ca
usa
ecp
measur
fluoroenzym
assay
unicap
system
pharmacia
uppsala
sweden
accord
manufactur
instruct
sensit
test
respect
pgml
level
level
detect
elisa
assay
design
half
lower
level
detect
data
analys
dtt
use
mucolyt
sampl
process
significantli
interfer
enzym
immunoassay
demonstr
comparison
assay
recombin
cytokin
without
addit
dtt
sampl
ad
dtt
result
recoveri
protein
compar
sampl
without
dtt
inulin
measur
method
adapt
nasal
secret
cytokin
express
per
millilitr
sputum
nasal
secret
main
outcom
leucocyt
total
differenti
count
solubl
mediat
concentr
sputum
eosinophil
lymphocyt
count
nlf
cell
count
normal
distribut
transform
normal
sputum
eosinophil
lymphocyt
prior
analysi
baselin
baselin
comparison
sputum
differenti
count
group
analys
student
unpair
baselin
comparison
group
nlf
cell
count
solubl
mediat
analys
chang
baselin
sputum
differenti
count
sputum
nlf
concentr
day
normal
distribut
analys
use
repeat
measur
manova
analysi
techniqu
allow
investig
chang
time
within
group
time
effect
differ
group
group
effect
differ
effect
time
group
interact
solubl
mediat
ecp
neutrophil
cell
count
nlf
markedli
skew
therefor
analys
use
relationship
chang
neutrophil
assess
pearson
correl
lrt
spearman
rank
correl
urt
chang
neutrophil
day
also
compar
chang
methacholin
symptom
score
day
taken
data
report
previous
pearson
correl
spearman
rank
correl
accord
data
distribut
sputum
cell
count
avail
occas
possibl
follow
reason
failur
expector
sampl
less
leucocyt
count
cytospin
sampl
exclud
day
due
intercurr
wild
infect
nasal
lavag
data
obtain
occas
possibl
follow
reason
nasal
sport
injuri
sampl
exclud
day
due
wild
infect
vast
major
nasal
lavag
sampl
obtain
throughout
studi
produc
return
volum
greater
ml
day
symptomat
phase
ill
volum
nlf
return
mean
ci
ml
volum
mean
ci
ml
viabil
cell
gener
good
cold
nasal
sampl
rang
sputum
sampl
rang
final
squamou
contamin
gener
median
sputum
sampl
greater
nasal
sampl
median
median
valu
cell
type
nlf
zero
subject
group
baselin
signific
differ
group
small
increas
total
leucocyt
cell
count
seen
group
cold
tabl
largest
chang
baselin
seen
day
larger
evw
group
small
increas
nasal
lavag
neutrophil
count
group
cold
studi
signific
differ
two
group
tabl
neutrophil
predomin
nlf
cell
throughout
studi
signific
correl
chang
nlf
neutrophil
urt
symptom
score
day
r
seen
day
r
differ
atop
subject
evw
group
cold
chang
neutrophil
count
baselin
day
median
chang
quartil
respect
signific
chang
eosinophil
either
atop
subject
cold
evw
group
median
chang
quartil
baselin
day
respect
small
increas
total
leucocyt
cell
count
seen
group
cold
tabl
chang
seen
subject
without
symptomat
cold
differ
seen
group
baselin
cell
differenti
count
tabl
signific
increas
proport
sputum
neutrophil
seen
evw
group
cold
day
return
toward
baselin
day
reciproc
effect
proport
macrophag
tabl
fig
effect
control
group
cold
differ
group
signific
differ
seen
sputum
lymphocyt
eosinophil
studi
inde
low
number
cell
present
relationship
chang
neutrophil
chang
symptom
score
day
day
maxim
chang
neutrophil
explor
signific
correl
r
found
howev
signific
correl
chang
sputum
neutrophil
total
lrt
symptom
score
whole
studi
period
r
subject
evw
cold
trend
toward
increas
nasal
day
return
toward
baselin
day
seen
control
fig
signific
differ
atop
subject
cold
chang
day
mean
differ
ci
pgml
respect
although
atop
subject
tend
higher
valu
subject
cold
nlf
concentr
level
detect
although
level
increas
subject
cold
increas
modest
signific
differ
group
overal
chang
nasal
ecp
although
subject
group
modest
increas
day
subgroup
analysi
atop
evw
subject
cold
day
also
show
signific
differ
median
quartil
pgml
respect
assay
sensit
pgml
major
subject
group
signific
correl
chang
concentr
urt
symptom
score
day
r
respect
howev
chang
concentr
day
significantli
correl
total
urt
score
whole
studi
period
r
weak
signific
correl
found
chang
neutrophil
baselin
day
r
thu
signific
interrelationship
urt
symptom
neutrophil
count
ill
cold
signific
increas
sputum
seen
evw
group
day
return
toward
baselin
day
tabl
fig
pattern
seen
control
signific
differ
group
tabl
subject
cold
level
detect
although
cold
increas
modest
signific
differ
group
signific
chang
sputum
ecp
either
group
subgroup
analysi
atop
evw
subject
cold
also
show
signific
chang
baselin
median
quartil
ecp
day
pgml
respect
major
sampl
level
level
detect
assay
chang
sputum
concentr
baselin
day
weakli
correl
lrt
neutrophil
differenti
count
r
lrt
symptom
score
day
r
total
lrt
symptom
score
r
experiment
infect
laboratori
strain
viru
differ
sever
respect
wild
infect
abil
cultur
viru
trigger
lrt
symptom
may
well
affect
attenu
well
unknown
factor
although
prove
case
previou
studi
dose
rout
inocul
clearli
differ
wild
situat
minor
import
present
studi
effect
proof
principl
evw
distinct
disord
volunt
inocul
activ
viru
possibl
may
asymptomat
infect
respond
mediat
suspens
medium
inflammatori
respons
asymptomat
infect
would
act
minim
differ
symptomat
asymptomat
group
affect
differ
viral
wheezer
control
clinic
cold
group
would
requir
exclud
interfer
recent
publish
data
group
suggest
activ
viru
produc
asymptomat
pathogen
effect
urt
epithelium
medium
contain
ultraviolet
treat
henc
inactiv
viru
pathogen
effect
two
group
ident
mani
characterist
although
atop
viral
wheez
group
atopi
thought
predispos
individu
sever
urt
ill
experiment
hrv
infect
studi
could
confound
factor
howev
find
atopi
factor
develop
urt
symptom
nasal
neutrophil
respons
model
although
number
small
nine
seven
atop
respect
viral
wheez
group
cold
allerg
rhiniti
also
known
predispos
subject
sever
urt
symptom
four
subject
histori
allerg
rhiniti
group
unlik
account
inflammatori
respons
seen
repeat
sputum
induct
h
apart
use
high
dose
hyperton
salin
ml
mlmin
caus
concentr
ecp
neutrophil
count
increas
approxim
pavord
review
problem
suggest
effect
may
relat
dose
hyperton
salin
use
present
studi
use
less
half
amount
hyperton
salin
given
rate
mlmin
chang
neutrophil
seen
sputum
control
without
cold
despit
repeat
induct
h
apart
repeat
nasal
lavag
could
wash
convers
recruit
cell
nasal
epithelium
repeat
studi
subject
without
cold
good
agreement
cell
count
repeat
nlf
interv
intraclass
correl
coeffici
respect
slightli
poorer
repeat
day
suggest
effect
cell
recruit
recruit
problem
current
studi
asymptomat
control
cell
nlf
stage
minor
effect
would
diminish
real
differ
group
recent
studi
demonstr
addit
proteas
inhibitor
markedli
enhanc
recoveri
cytokin
particular
sputum
could
one
reason
found
undetect
level
mani
factor
believ
import
pathogenesi
evw
exacerb
wheez
associ
one
wide
rang
infect
viral
strain
suggest
host
respons
factor
rather
viru
specif
predomin
either
heighten
abnorm
inflammatori
respons
viru
infect
undu
physiolog
respons
normal
inflamm
form
bronchial
could
central
abnorm
wheez
respons
clear
evid
rel
neutrophilia
lrt
along
elev
evw
group
also
demonstr
two
studi
wild
type
viru
exacerb
atop
asthma
latter
also
found
eosinophilia
increas
ecp
lrt
low
level
eosinophil
ecp
present
studi
suggest
eosinophil
import
evw
differ
cellular
physiolog
respons
atop
subject
evw
mechan
atopi
eosinophil
inflamm
must
involv
evw
adult
evw
suffer
urt
symptom
similar
healthi
control
although
studi
trend
toward
sever
symptom
greater
degre
nasal
inflamm
lrt
neutrophilia
appear
specif
evw
subject
tradit
propos
neutrophil
limit
damag
caus
viral
respiratori
tract
infect
although
may
also
caus
tissu
damag
releas
cytotox
protein
elastas
myeloperoxidas
free
radic
mediat
neutrophil
caus
lrt
tissu
damag
wheez
clearli
cell
could
involv
pathogenesi
evw
studi
viral
urti
except
respiratori
syncyti
viru
rsv
bronchiol
found
direct
relationship
lrt
neutrophil
cell
differenti
count
lrt
symptom
seem
like
factor
also
involv
evw
suggest
cascad
differ
mechan
recruit
activ
lymphocyt
releas
cytokin
chemokin
airway
remodel
alter
neural
respons
combin
produc
chang
airway
physiolog
demonstr
increas
evid
common
respiratori
virus
directli
infect
lret
might
directli
influenc
mechan
inflamm
import
ill
search
potenti
therapeut
intervent
focu
stimulu
mechan
lrt
cell
recruit
role
symptom
product
possibl
indirect
mechan
could
link
urt
lrt
remain
sever
potenti
link
exist
nasal
provoc
cold
air
shown
produc
increas
airway
resist
seen
stimulu
deliv
mouth
asthmat
suggest
presenc
nasobronchi
neural
reflex
nose
also
play
import
protect
role
lrt
condit
filter
inspir
air
also
abil
gener
immun
respons
possibl
nasal
immun
respons
cell
activ
lrt
effect
via
circul
cell
mediat
need
explor
mechan
requir
host
factor
discrimin
healthi
wheezi
subject
independ
atopi
report
role
inflamm
urt
lrt
experiment
hcov
infect
adult
histori
evw
demonstr
modest
neutrophil
inflamm
lrt
evw
subject
evid
eosinophil
accumul
activ
neutrophil
like
involv
mechan
lead
evw
basi
excess
accumul
evw
sought
